Chicago Capital LLC Has $51.80 Million Holdings in Insulet Corporation $PODD

Chicago Capital LLC increased its stake in Insulet Corporation (NASDAQ:PODD) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 182,231 shares of the medical instruments supplier’s stock after purchasing an additional 2,625 shares during the period. Insulet makes up 1.3% of Chicago Capital LLC’s holdings, making the stock its 29th largest position. Chicago Capital LLC owned approximately 0.26% of Insulet worth $51,797,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Winnow Wealth LLC bought a new position in Insulet in the 3rd quarter valued at about $862,000. Nordea Investment Management AB raised its holdings in Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after acquiring an additional 142,922 shares during the period. Machina Capital S.A.S. bought a new position in Insulet in the 3rd quarter valued at about $2,778,000. Jain Global LLC raised its holdings in Insulet by 148.2% in the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in Insulet by 38.1% in the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after acquiring an additional 12,754 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PODD. BTIG Research lowered their price target on shares of Insulet from $380.00 to $320.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Evercore decreased their target price on shares of Insulet from $340.00 to $240.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Truist Financial decreased their target price on shares of Insulet from $360.00 to $315.00 and set a “buy” rating on the stock in a research report on Wednesday. TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a research report on Monday, January 26th. Finally, Oppenheimer decreased their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Nineteen investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $334.38.

Insiders Place Their Bets

In related news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.39% of the stock is owned by corporate insiders.

Insulet Stock Performance

NASDAQ PODD opened at $203.73 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $14.11 billion, a price-to-earnings ratio of 58.21, a P/E/G ratio of 1.21 and a beta of 1.47. The firm’s 50 day simple moving average is $227.50 and its 200 day simple moving average is $275.74. Insulet Corporation has a 1 year low of $194.61 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same quarter last year, the business posted $1.15 EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.